The Switch To Cell-Free DNA: Streamlining Advanced Therapy Manufacturing

Advanced therapy manufacturing is under increasing pressure to deliver speed, consistency, and regulatory confidence — requirements that expose the limitations of plasmid‑based DNA production. Cell‑free DNA manufacturing offers a fundamentally different approach, removing bacterial fermentation from the equation and simplifying both upstream and downstream processes.

By eliminating endotoxins, antibiotic resistance genes, and lengthy cell banking steps, cell‑free workflows reduce risk while enabling faster turnaround and greater flexibility. This shift is particularly impactful for advanced and personalized therapies, where timelines are tight and batch sizes are small. Streamlined quality control strategies, higher process consistency, and scalability through scale‑out models make cell‑free DNA a practical foundation for next‑generation medicines.

Explore the full blog to see how moving away from plasmids can help modernize manufacturing strategies and better align production with today’s therapeutic demands.